Cost-effectiveness of hypertension therapy according to 2014 guidelines.

ABSTRACT:

Background

On the basis of the 2014 guidelines for hypertension therapy in the United States, many eligible adults remain untreated. We projected the cost-effectiveness of treating hypertension in U.S. adults according to the 2014 guidelines.

Methods

We used the Cardiovascular Disease Policy Model to simulate drug-treatment and monitoring costs, costs averted for the treatment of cardiovascular disease, and quality-adjusted life-years (QALYs) gained by treating previously untreated adults between the ages of 35 and 74 years from 2014 through 2024. We assessed cost-effectiveness according to age, hypertension level, and the presence or absence of chronic kidney disease or diabetes.

Results

The full implementation of the new hypertension guidelines would result in appro

SUBMITTER: Moran AE 

PROVIDER: S-EPMC4403858 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature